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ABSTRACT 
Duchenne muscular dystrophy (DMD) is an X-linked recessive disease caused by mutations in the 
dystrophin gene and is characterized by muscle degeneration and death. DMD affects males; 
females being asymptomatic carriers of mutations. However, some of them manifest symptoms due 
to a translocation between X chromosome and an autosome or to a heterozygous mutation leading 
to inactivation of most of their normal X chromosome. Six symptomatic female carriers and two 
asymptomatic were analyzed by: I) Segregation of STRs-(CA)n and MLPA assays to detect a 
hemizygous alteration, and II) X chromosome inactivation pattern to uncover the reason for 
symptoms in these females. The symptomatic females shared mild but progressive muscular 
weakness and increased serum creatin kinase (CK) levels. Levels of dystrophin protein were below 
normal or absent in many fibers. Segregation of STRs-(CA)n revealed hemizygous patterns in three 
patients, which were confirmed by MLPA. In addition, this analysis showed a duplication in 
another patient. X chromosome inactivation assay revealed a skewed X inactivation pattern in the 
symptomatic females and a random inactivation pattern in the asymptomatic ones. Our results 
support the hypothesis that the DMD phenotype in female carriers of a dystrophin mutation has a 
direct correlation with a skewed X-chromosome inactivation pattern.  
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INTRODUCTION 
      Duchenne muscular dystrophy (DMD) and the milder allelic Becker muscular dystrophy (BMD) 
are X-linked recessive diseases caused by absent or abnormal dystrophin, respectively, in skeletal 
muscle, which results in early muscle degeneration. DMD is a fatal disease that affects 1:3500 
newborn males, while BMD is less severe and less frequent [1]. Both dystrophies are caused by 
mutations, mostly deletions, in the dystrophin gene [2,3]. One third of the cases arise from new 
mutations, while the remaining two thirds are inherited [4,5]. DMD and BMD usually affect males, 
with the majority of females being asymptomatic carriers. However, some of these females can 
reveal symptoms that vary from mild muscle weakness to a more severe clinical course and are 
classified as manifesting or symptomatic carriers [6,7,8,9,10]. Studies on muscle biopsy suggest 
that female dystrophinopathy patients show a skewed X inactivation, where the X chromosome that 
carries the normal dystrophin gene is preferentially inactivated [11,12]. Many of these symptomatic 
carriers have gross chromosomal rearrangements due to translocation between the X chromosome 
and an autosome, with one breakpoint involving the DMD gene [13]. In these cases the normal X 
chromosomes appear to be preferentially inactivated since the dystrophin levels are below normal, 
leading to DMD or to a milder variant [14]. On the other hand, a small number of females 
heterozygous for dystrophin mutations, have most of their normal X chromosome randomly 
inactivated, and manifest mild DMD symptoms [15]. Furthermore, a different X inactivation pattern 
was seen in pairs of monozygotic twins heterozygous for mutation in the dystrophin gene, which 
resulted in clinical manifestation in only one of them [16]. 
        It is more difficult to ascertain the DMD mutations in female carriers than those in males 
because the presence of the normal X chromosome masks the alteration in its mutant counterpart 
[17]. Thus, in order to detect mutations (mostly deletions) in females clinically diagnosed with 
muscle disease, more laborious and expensive methods need to be used than for analysis of male 
patients. These methods include segregation analysis of short tandem-repeat (STR) (CA)n 
polymorphisms and MLPA assay, which are able to detect hemizigous patterns and thereby reveal 
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the mutated DMD gene in female-carriers. The use of (STR) (CA)n polymorphisms, located 
throughout the dystrophin gene including the deletion-prone regions [18], is not as informative as 
MLPA analysis, however, both methods are essential for validation of the identified mutations. 
       The determination of maternal and paternal X chromosome activation status is useful for the 
analysis of non-random X inactivation patterns. One of the methods to test the X inactivation is 
based on the methylation-sensitivity of the restriction enzymes HpaII and HhaI [19]. It was shown 
that the methylation of HpaII and HhaI sites in the first exon of the human androgen-receptor locus 
correlates with X inactivation, moreover, the presence of an STR close to this site allows the use of 
a PCR assay to identify the methylation pattern of the maternally and paternally derived X 
chromosomes. 
       This study aimed to analyze six symptomatic and two asymptomatic female carriers using a 
strategy that includes: i) identification of the hemizygous patterns in the dystrophin gene by 
segregation of STRs-(CA)n markers and MLPA assay; and ii) determination of the X chromosome 
inactivation pattern. Comparing these results with clinical and histopathologic data provides a 
correlation between genotype and phenotype and thus unable us to uncover the reason for the 
manifesting DMD status in these females. 
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MATERIALS AND METHOD 
Patients 
Six females with muscular dystrophy and no DMD history and two females without these 
symptoms were referred for a differential diagnosis of DMD by several hospitals in Argentina. The 
a priori diagnosis was established by current clinical, biochemical and histological criteria. After 
approval of the study protocol by the Bioethical Committee of Hospital de Clinicas “Jose de San 
Martin”, informed consent for genetic analyses was signed by the patients. The clinical features are 
depicted in Table 1. The six symptomatic females presented with muscle alterations compatible 
with dystrophinopaty and several of them, in addition, with learning and behavioural anomalies. 
One of the females had a DMD associated with an autism syndrome. The two asymptomatic 
females showed minor myopathic signs such as muscle cramps, myalgia and one of them (#60), a 
mild cardiac dysfunction. Both females presented with high CK levels.  
Mutation analysis 
Mutation screening was performed by segregation analysis of Short Tandem Repeats of (CA)n 
(STRs-(CA)n) and Multiplex Ligation-dependent Probe Amplification (MLPA). The DNA from 
peripheral blood leukocytes of probands and their parents was isolated by the CTAB method [20]. 
Nine STR-(CA)n located in the following introns: 7, 25, 44, 45, 49, 50, 62,79 and the 5´ region of 
exon 1 were assayed as previously described [17]. Briefly, 120 ng of genomic DNA were mixed 
with 15 pmol of each primer, of them end-labelled with 32P, in a total volume of 15 μl containing 
10mM Tris-HCl, pH 8.3, 50mM KCl, 1.5mM MgCl2, 0.2mM each deoxyribonucleotide 
triphosphate, and 0.75 units of Taq polymerase (Inbio Highway, Argentina). The samples were 
heated to 94ºC for 4 min, followed by 25 cycles of DNA denaturation (94ºC for 30s), annealing 
(60ºC for 30s) and polymerization (72ºC for 30s) and a final incubation at 72ºC for 10min. Next, 2-
4 μl of the PCR products were electrophoresed on denaturing-polyacrylamide sequencing gel. 
Autoradiography of the dried gel was performed at room temperature for 1-3 days. MLPA was 
carried out with two SALSA probemixes, 034 and 035, according to the manufacturer´s 
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recommendations (MRC Holland, Amsterdam, Netherlands) in order to screen all the dystrophin 
exons. PCR products were analyzed on an AB1 3130 automated sequencer using Genescan software 
(Applied Biosystem). The dosage quotient was calculated using Gene Marker software. 
X-chromosome inactivation pattern analysis (HUMARA assay) 
Genomic DNA samples were isolated from peripheral blood leukocytes (PBL) by salting out 
procedure [21] to detect X-chromosome inactivation by the AR (human androgen receptor gene) 
assay as was originally described with minor modifications [19]. Briefly, for each patient’s DNA 
sample, two reactions were prepared: two μg of DNA were either treated (T) with 20 U Hpa II 
(methylation sensitive restriction enzyme), or non-treated (N), i.e., incubated with the enzyme 
digestion buffer with not enzyme. Both reactions were carried out in 20 μl of final volume at 37°C 
overnight and stopped by heating the mixture at 95°C for 10 min. Two μl of treated and non-treated 
DNA were amplified by touchdown-PCR, spanning a highly polymorphic (CAG)n repeat in the 
first exon of the AR gene (Xq11). T and N PCR products were separated on a polyacrylamide gel 
on an ABI3130XL automated sequencer. The amount of gene products from the two X 
chromosomes was determined by the use of SoftGenetics GeneMarker. XIP (X-inactivation pattern) 
was calculated as follows XIP = 100 – 50 (A’/A) (A+B) / (A’+B’), where A and B signals 
correspond to non-treated, and A’ and B’ correspond to Hpa II-treated. Statistical analysis was 
performed using Prism 5.0 GraphPad Software (USA). X-inactivation pattern was considered as 
random for values ≤ 80% (ratios ≤ 80:20), moderately skewed for values >80% and ≤ 90% and 
highly skewed for values > 90%, according to Amos-Landgraf et al. [22]. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 7 
RESULTS 
     Six female patients manifesting different grades of DMD plus two females not manifesting 
DMD but with some features suggesting a DMD carrier status, were studied (Table 1). The females 
with DMD symptoms represent 6% of the total DMD carrier females studied in our laboratory, 
which is consistent with previously reported data [6]. The age of disease onset in five of the 
symptomatic females was between 7 and 10. One of these patients (#499) had an onset of autism at 
the age of 3 with symptoms that included hyperactivity, impulsiveness and loss of previously 
acquired functions plus an onset of DMD at the age of 10. All these females shared myopathic 
changes on electromyograms and a progressive muscular weakness, which was less severe than in 
DMD males. Most of them are still able to walk, but with some problems such as frequent falls, 
fatigue, lameness and an inability to run. One of these patients (#482) became wheel-chair bound at 
the age of 19. The sixth female (#514), who was born from consanguineous parents, had an earlier 
onset, before the age of 6, and presented with more severe symptoms. This female became wheel-
chair bound at the age of 6 and died at the age of 13 from heart failure. Four of the females (#287, 
334, 433 and 499) showed behavioural and mild learning anomalies, however, all of them finished 
elementary school and three were attending high school. The remaining two females, the autistic 
patient (#499) and the one with more severe DMD symptoms (#514), did not attend elementary 
school. The patient who became wheel-chair bound at the age of 19 (#482) had a difficulty in using 
her hands, however, she had skills for painting. 
        The biochemical and genetic data of the patients indicate that the CK levels varied between 
462 and 5070 U/L in the six symptomatic females (Table 1). The muscle dystrophin protein levels, 
analyzed by immunohistochemistry, were lower than normal (#287, 334, 433), or there was an 
absence of dystrophin in many of the fibers (#499). These results are consistent with the 
dystrophinopathy syndrome. The two females not expressing DMD (#60 and 645) had had mild 
myopathic signs, however, they presented with biochemical or histological data that suggest a DMD 
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carrier status. They showed high CK levels and one of them (#645) also showed a decreased 
dystrophin in all muscle fibers. 
       Detection of deletions in the dystrophin gene was previously arrived at by segregation analysis 
of STRs-(CA)n in families with affected females. Figure 1 shows the pedigrees and haplotypes of 
six families. Three of the females (#287, 334 and 433) showed a hemizygous pattern with an 
absence of maternal or paternal allele at the loci of 7A, 49/50 and 45 respectively, which revealed a 
deletion in these regions of the dystrophin gene (STRs results of #287 and #334 were already 
reported [17]). There was no absence of any parental allele in the haplotypes of the other three 
affected females. One of these patients, #514, displayed a homozygosity for 6 of the 7 STRs studied 
with the exception of STR 49. Her mother was also homozygous for 6 of the STRs and shared these 
alleles with the father. These results revealed the parents’ consanguinity. In addition, the paternal 
allele at the 49 STR locus changed to a smaller one (d→e) during transmition to his daughter.  
      MLPA analysis confirmed the results of STRs segregation assay showing deletions of the exons 
7-20 (#287), 45-52 (#334) and 45 (#433). In addition, this analysis revealed a duplication of exons 
18-28 in patient #499. No alterations were detected in the dystrophin gene by MLPA in two 
affected females (#482, #514) nor in the two females not expressing DMD. 
      The pattern of X-chromosome inactivation (XIP) in the six symptomatic and the two 
asymptomatic females is depicted in Figure 2. All the females were found to be heterozygous at the 
AR locus. The symptomatic females showed an extremely skewed X-chromosome inactivation 
pattern: XIP>90%, whereas, the two females not expressing DMD (#60 and 645) showed a random 
pattern of inactivation: XIP 52% and 71% respectively (Figure 2 and Table 1). 
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DISCUSSION 
      In order to clarify the mechanism responsible for clinical symptoms in female DMD mutation-
carriers we studied six females with a clinical diagnosis of dystrophinopathy and two females 
without dystrophinopathy, but with biochemical/histological data suggesting a DMD carrier status. 
Furthermore, their genotypic and phenotypic profiles were compared. The clinical presentation of 5 
of the females, who are currently aged between 17 and 41, was similar to mild dystrophinopathy, 
characterized by a later onset and less severe muscle problems than in DMD males. Of note is that 
one of the females (#499) presented clinical features of two syndromes: autism and 
dystrophinopathy. Behavioral and mild learning anomalies were apparent in most females but there 
was a severe anomaly in the autistic patient. In contrast to these 5 female patients the sixth female 
(#514) showed severe DMD symptoms, like those displayed in DMD males. She had serious 
walking and respiratory problems and died at the early age of 13. The two females without 
dystrophinopathy (#60 and 645) did not share the clinical features of the symptomatic patients.  
      The immunostaining of muscle biopsy with antidystrophin antibody highlighted a reduced 
dystrophin labelling of the fibers and a mosaic distribution of dystrophin-positive (or attenuated) 
and dystrophin-negative fibers. However, there was no correlation between the percentage of 
negative fibers and the clinical presentation since one of the females (#645) without 
dystrophinopathy and a mildly increased CK level, showed a marked decrease of dystrophin, 
indicating a DMD carrier status. These results are in full agreement with other reports [23]. 
      Segregation of STRs and MLPA analyses allowed for the detection of deletions in three females 
and a duplication in one of the patients. Two of these mutations were clustered in the central hot 
spot region and two other mutations, one deletion and one duplication were located at the 5´ region 
of the gene, which is a common site for duplications [9]. All the mutations were out of frame. No 
gross deletions/duplications were found in two of the female patients (#482 and 514) nor were they 
found in the two females not expressing DMD (#60 and 645), suggesting an absence of gross 
rearrangements and the presence of point mutations as the cause of dystrophinopathy or carrier 
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status. Interestingly, one of the patients (#514) who was homozygous for most STR loci due to her 
parents´ consanguinity (cousins), additionally showed a retraction in the paternal 49 STR-allele. 
This patient was the one that had a severe muscular disease and the only one who died at an early 
age. The absence of gross rearrangements revealed by STRs and MLPA analyses suggests that there 
was no chromosomal translocation between X and an autosome. Thus, another type of mutation 
would be responsible for the dystrophinopathy, and the severe presentation may be due to additional 
alterations in a glycoprotein complex or in other factors resulting from parental consanguinity.    
      Skewed X chromosome inactivation has been proposed as a possible explanation for the 
presence of DMD-symptoms in female carriers of dystrophin gene mutations. Such females should 
have an active X chromosome with the mutation and an inactive normal X chromosome. This 
hypothesis has been proved in females with an X-autosome translocation, in whom the X-autosome 
can not be inactivated and thus, the normal X-chromosome became inactivated in all the muscle 
cells, leading to severe DMD-like symptoms [9]. However, in cases with a skewed X-inactivation in 
the majority of the fibers (for example 80%) some muscle cells should have dystrophin-positive 
fibers. In these cases the results concerning the correlation between the patient phenotype and an X-
inactivation pattern are controversial [7,8,22]. All the symptomatic females studied in our 
laboratory presented a skewed X-inactivation pattern (XIP), showing a relationship between the 
clinical phenotype and the pattern of X-inactivation. No translocations have been revealed by the 
methods used for detection of gross rearrangements. These data suggest a different reason for a 
skewed X-inactivation than the presence of an autosomic fragment joined to X chromosome with a 
mutated dystrophin gene. The lack of translocation in the only patient with a severe form of 
dystrophinopathy (#514) correlates with the partially skewed pattern of X-inactivation, unlike to 
that observed in patients with an X-autosome translocation [9].  
      In summary, different findings concerning the correlation between DMD symptoms and a 
skewed X chromosome inactivation in females have been reported previously. Our results support 
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the hypothesis that the DMD phenotype in female carriers of dystrophin mutations is connected to a 
skewed X chromosome inactivation pattern, leading to less expression of the wild type dystrophin. 
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LEGEND TO FIGURES 
 
Figure 1: Pedigrees of six families with DMD symptomatic female carriers. The haplotypes resulted 
from segregation analysis are shown next to each analyzed individual. They are denoted by 
assigning arbitrary letters to each variation. dln: deletion. 
 
Figure 2: X-chromosome inactivation pattern in six symptomatic carriers of Duchenne Muscular 
Dystrophy and in two asymptomatic females. N indicates non-treated and T treated with Hpa II. 
XIP indicates X-chromosome inactivation pattern which was considered as random for values ≤ 
80% (ratios ≤ 80:20), moderately skewed for values >80% and ≤ 90% and highly skewed for values 
> 90%. Each single signal corresponds to a PCR amplified allele of the (CAG)n repeat within the 
first exon of the AR gene, on an ABI3130XL automated sequencer. To quantify the relative 
inactivation, the AUC (area under the curve) of both alleles (non-treated and treated DNA) was 
measured using the GeneMarker software. The HUMARA assay shows an extremely skewed X-
chromosome inactivation pattern, XIP>90%, in all the six symptomatic cases (in the upper part of 
the figure: #287, 334, 433, 482, 499 and 514) and a random pattern of X-inactivation, XIP 52% and 
71%, in the two asymptomatic cases (in the bottom of the figure: #60 and 645). 
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Table 1: Clinical, biochemical and molecular data of symptomatic female carriers. X-inactivation 
pattern 
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462:27
y
ε 
850:28
y 
Dys
λ
 1,2,3 
Lower 
level than 
normal 
Hemizygos
ity 
at 7A locus 
Absence of  
maternal 
allele 
Dele
tion: 
Exo
ns 7-
29 
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334  7 25 Myopat
hic 
change
s 
Progres
sive 
weakne
ss 
Walki
ng 
proble
ms 
No 
runnin
g 
Behavi
oural & 
mild 
learnin
g 
anomal
ies at 
High 
school 
4240:8
y 
1750:1
4y 
Dys 1,2,3 
Lower 
level than 
normal 
Hemizygos
ity 
at 49/50 
loci 
Absence of  
paternal 
allele 
Dele
tion: 
Exo
ns 
45-
52 
100:0 
433  8 17 Myopat
hic 
change
s 
Progres
sive 
weakne
ss 
Walki
ng 
proble
ms 
No 
runnin
g 
Behavi
oural & 
mild 
learnin
g 
anomal
ies at 
High 
school 
1630:8
y 
Dys 2,3: 
Negative 
fibers, 
Isolated 
positive 
Altered fiber 
structure 
Increase of 
endomysial 
fibrosis and 
of internal 
nuclei. 
Hemizygos
ity 
at 45 locus 
Absence of  
maternal 
allele 
Dele
tion:  
Exo
n 45 
100:0 
482  8 21 Myopat
hic 
change
s 
Progres
sive 
Wheel
-chair 
bound 
at 19 
years 
Diffic
Normal 
learnin
g:  
Elemen
tary 
school 
5070:1
2y 
Not 
determine
d
 
Not 
detected 
No 
gros
s 
Rear
rang
m. 
100:0 
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weakne
ss 
ulty in 
the 
use of 
hands 
 
finishe
d 
Paintin
g Skills   
499  3: 
Autis
m 
~10: 
DMD 
24 Myopat
hic 
change
s 
Progres
sive 
weakne
ss 
Autis
m 
Walki
ng 
proble
ms 
Inability 
to hold  
objects 
Convu
lsions  
Aggres
sivenes
s 
No 
speakin
g. 
Special 
care 
needs 
 
5000:1
5y 
Dys 1,2,3:  
Partial 
deficiency
:  
15-30% of 
fibers. 
Mosaic 
distributio
n 
Not 
detected 
Dupl
icati
on: 
Exo
ns 
18-
28 
97:3 
514 Before 
6 
Dead:13 
(Cardiac  
strike) 
Progres
sive 
weakne
ss 
Wheel 
chair 
bound: 
6 years 
Breathi
ng 
diffic.
ν 
Incomp
lete 
school 
Not 
reporte
d 
Not 
determine
d 
Not 
detected 
No 
gros
s 
Rear
rang
em. 
90:10 
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645 9 17 No 
Myopat
hic 
change
s 
9 
years: 
Freque
nt falls 
17 
years: 
Norma
l 
walkin
g/runn
ing 
Normal 
learnin
g 
Univers
ity 
study 
315:9y Dys 1,2,3: 
Decrease: 
all muscle 
fibers 
Not 
detected 
No 
gros
s 
Rear
rang
em. 
72:28 
 60 4 17 No 
Myopat
hic 
Change
s 
4 
years: 
Cramp
s 
Decrea
sed 
strengt
h 
Mild 
cardia
c 
dysfun
ction 
Behavi
oural & 
learnin
g 
anomal
ies 
3642:1
7y 
Dys 1,2,3: 
 Normal 
Not 
detected 
No 
gros
s 
Rear
rang
em. 
52:48 
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*ID: patient´s identification number; 
†
EMG: electromyography;
 **
CK: creatine kinase; 
‡
U/L: units 
per liter; 
§
STRs: short tandem repeats; 
α
MLPA: multiplex ligation-dependent probe amplification; 
β
XIP: chromosome X inactivation pattern; 
γ
MR: mental retardation; 
δ
NMR: nuclear magnetic 
resonance; 
ε
y: years; 
λ
DYS: dystrophin; 
ν
diffic.: difficult. 
